Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review
- PMID: 27128911
- PMCID: PMC4881459
- DOI: 10.3390/ijms17050633
Definitions of Normal Liver Fat and the Association of Insulin Sensitivity with Acquired and Genetic NAFLD-A Systematic Review
Abstract
Non-alcoholic fatty liver disease (NAFLD) covers a spectrum of disease ranging from simple steatosis (NAFL) to non-alcoholic steatohepatitis (NASH) and fibrosis. "Obese/Metabolic NAFLD" is closely associated with obesity and insulin resistance and therefore predisposes to type 2 diabetes and cardiovascular disease. NAFLD can also be caused by common genetic variants, the patatin-like phospholipase domain-containing 3 (PNPLA3) or the transmembrane 6 superfamily member 2 (TM6SF2). Since NAFL, irrespective of its cause, can progress to NASH and liver fibrosis, its definition is of interest. We reviewed the literature to identify data on definition of normal liver fat using liver histology and different imaging tools, and analyzed whether NAFLD caused by the gene variants is associated with insulin resistance. Histologically, normal liver fat content in liver biopsies is most commonly defined as macroscopic steatosis in less than 5% of hepatocytes. In the population-based Dallas Heart Study, the upper 95th percentile of liver fat measured by proton magnetic spectroscopy (¹H-MRS) in healthy subjects was 5.6%, which corresponds to approximately 15% histological liver fat. When measured by magnetic resonance imaging (MRI)-based techniques such as the proton density fat fraction (PDFF), 5% macroscopic steatosis corresponds to a PDFF of 6% to 6.4%. In contrast to "Obese/metabolic NAFLD", NAFLD caused by genetic variants is not associated with insulin resistance. This implies that NAFLD is heterogeneous and that "Obese/Metabolic NAFLD" but not NAFLD due to the PNPLA3 or TM6SF2 genetic variants predisposes to type 2 diabetes and cardiovascular disease.
Keywords: PNPLA3; TM6SF2; insulin resistance; liver fat; obesity.
Figures
Similar articles
-
Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease.J Gastroenterol Hepatol. 2018 Jun;33(6):1277-1285. doi: 10.1111/jgh.14056. Epub 2018 Feb 26. J Gastroenterol Hepatol. 2018. PMID: 29193269
-
Circulating triacylglycerol signatures and insulin sensitivity in NAFLD associated with the E167K variant in TM6SF2.J Hepatol. 2015 Mar;62(3):657-63. doi: 10.1016/j.jhep.2014.10.010. Epub 2014 Oct 19. J Hepatol. 2015. PMID: 25457209
-
PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.Surg Obes Relat Dis. 2016 Dec;12(10):1838-1846. doi: 10.1016/j.soard.2016.06.004. Epub 2016 Jul 1. Surg Obes Relat Dis. 2016. PMID: 27576208
-
Non-alcoholic fatty liver disease and risk of type 2 diabetes.Best Pract Res Clin Endocrinol Metab. 2016 Jun;30(3):385-95. doi: 10.1016/j.beem.2016.06.006. Epub 2016 Jun 23. Best Pract Res Clin Endocrinol Metab. 2016. PMID: 27432073 Review.
-
Diagnosis of non-alcoholic fatty liver disease (NAFLD).Diabetologia. 2016 Jun;59(6):1104-11. doi: 10.1007/s00125-016-3944-1. Epub 2016 Apr 18. Diabetologia. 2016. PMID: 27091184 Review.
Cited by
-
Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review.Curr Vasc Pharmacol. 2024;22(3):187-202. doi: 10.2174/0115701611285401240110074530. Curr Vasc Pharmacol. 2024. PMID: 38321893
-
The "obese liver" and gastrointestinal cancer risk.Transl Gastroenterol Hepatol. 2020 Jul 5;5:44. doi: 10.21037/tgh.2019.12.07. eCollection 2020. Transl Gastroenterol Hepatol. 2020. PMID: 32632395 Free PMC article. No abstract available.
-
Emerging Perspectives on the Set of Conditions That Lead to the Emergence of Metabolic Syndrome.J Pers Med. 2023 Dec 26;14(1):32. doi: 10.3390/jpm14010032. J Pers Med. 2023. PMID: 38248733 Free PMC article. Review.
-
Changes in the immune system - the key to diagnostics and therapy of patients with non-alcoholic fatty liver disease.Cent Eur J Immunol. 2018;43(2):231-239. doi: 10.5114/ceji.2018.77395. Epub 2018 Jun 30. Cent Eur J Immunol. 2018. PMID: 30135638 Free PMC article. Review.
-
State of Knowledge on Molecular Adaptations to Exercise in Humans: Historical Perspectives and Future Directions.Compr Physiol. 2022 Mar 9;12(2):3193-3279. doi: 10.1002/cphy.c200033. Compr Physiol. 2022. PMID: 35578962 Free PMC article.
References
-
- Chalasani N., Younossi Z., Lavine J.E., Diehl A.M., Brunt E.M., Cusi K., Charlton M., Sanyal A.J. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Am. J. Gastroenterol. 2012;107:811–826. doi: 10.1038/ajg.2012.128. - DOI - PubMed
-
- Angulo P., Kleiner D.E., Dam-Larsen S., Adams L.A., Bjornsson E.S., Charatcharoenwitthaya P., Mills P.R., Keach J.C., Lafferty H.D., Stahler A., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149:389–397. doi: 10.1053/j.gastro.2015.04.043. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical